TMTPOST--Molecule Mind, a leading AI-driven protein design platform in China, has successfully raised hundreds of millions of yuan in Series A funding. The round was co-led by Cherami Investment and Shenzhen Capital Group, followed by SenseTime Guoxiang Capital and Ebica Capital.

The newly acquired funds will be used to expand the talent pool, enhance the technical platform, and accelerate the industrialization of AI-driven protein technology.

Founded in 2022 by renowned computational biologist Professor Xu Jinbo, Molecule Mind is dedicated to advancing protein design through AI. Xu is credited with pioneering the use of AI in protein folding, having solved the long-standing protein structure prediction challenge in 2016. His breakthrough laid the foundation for DeepMind’s AlphaFold, revolutionizing AI protein design.

Molecule Mind boasts a team of experts from top institutions like MIT, Yale University, California University of Technology (Caltech), Tsinghua University, and Peking University, alongside professionals from leading companies such as WuXi AppTech, Novozymes, Meta, Amazon, Baidu, and Alibaba.

The company's flagship product, MoleculeOS, is a one-stop AI platform for protein prediction, optimization, and design. Leveraging advanced machine learning and deep learning algorithms, the platform significantly enhances research efficiency in protein discovery and modification. Additionally, the company's NewOrigin AI model can design custom proteins in minutes, reducing lab costs and improving protein design effectiveness.

Molecule Mind has also partnered with top pharmaceutical companies to optimize key industrial enzymes and has achieved groundbreaking results in drug development by designing proteins with enhanced anti-tumor properties.

The company plans to use the funds to further expand its team and develop AI protein technology for industrial applications and commercialization.